Despite the huge improvements in diabetes technologies, such as glucose monitoring systems and insulin pumps, many people with diabetes do not meet glycemic control targets [23] and would benefit from greater flexibility and more individualized diabetes therapy. This evidence concerns the gene INS and diabetes mellitus.